... referred for deep vein thrombosis, 3 had history of deep vein thrombosis, 1 had both arterial thrombosis and a history of venous thrombosis; 2 had thrombocytopenia; 3 had stroke, 1 had a history of s troke. One patient had SLE according to ARA classification. The most frequent associated disease was cancer...

...Maria Benedetta Donati Thrombosis is the most frequent complication and the second cause of death in patients with overt malignant disease. Increasing evidence suggests that thrombotic episodes may also precede the diagnosis of cancer by months or years thus representing a potential marker...

... to aPC in patients with advanced cancer and examined the relationship of aPC resistance to other markers of coagulation activation. Methods: Patients (n = 39) had an established diagnosis of advanced cancer; controls (n = 20) were healthy persons. aPC resistance was measured as the ratio of activated...

...P.M. Mannucci In the last few years, several assays have been developed that permit the evaluation, with a high degree of sensitivity, of the level of activation of the coagulation system. Some of these tests have been used in cancer patients, in an attempt to monitor the risks of tumour...

...A.K. Kakkar; R.C.N. Williamson Patients with cancer are at increased risk for venous and arterial thromboembolism and the principal interventions in such patients – surgical operation, chemotherapy or venous catheterization – heighten this risk. Thromboprophylaxis is indicated in cancer patients...

...M. Levine Cancer patients are in a hypercoagulable state. The pathogenesis of thrombosis in malignancy is multifactorial with mechanisms including release of procoagulants by tumour cells, comorbid predisposing factors (bed rest, infection, surgery, etc.) and anti-cancer drugs. Cancer patients...

...P. McCulloch; W. Nieuwenhuizen; J. Douglas; G.D.O. Lowe; W.D. George Disturbances of coagulation were measured in breast cancer, colon cancer and benign breast disease using an enzyme immunoassay against total plasma fibrinogen and fibrin degradation products (TDP). Results were compared...

...D. Morgan; R.L. Edwards; F.R. Rickles Peripheral blood monocytes generate the procoagulant tissue factor in vitro and in vivo in response to stimulation by a variety of agents. Monocytes from cancer patients generate significantly increased tissue factor and a quantitative relationship exists...

... and in some cancer patients indicate that the functional status in terms of PCA of mononuclear phagocytes at ‘peripheral’ sites is not the same as that of macrophages at the tumor site (tumor-associated macrophages, TAM). Peripheral blood monocytes and/or peritoneal macrophages from V2-carcinoma-bearing...

.... Urokinase plasminogen activator Tumor-associated macrophages Cancer Haemostasis 18: 66-71 (1988) © 1988 S. Karger AG, Basel 0301 - 0 147/88/0181-006652.75/0 Expression of Plasminogen Activator as a Marker of Stimulation in Tumor-Associated Macrophages Luciana Mussoni, Maria Benedetta Donati Mario Negri...

... thromboplastin in relation to inflammatory diseases, cancer, disseminated intravascular coagulation and diseases of the blood vessels, thrombosis and atherosclerosis. 2 07 1984 9 09 1984 21 4 2009 © 1984 S. Karger AG, Basel 1984 Copyright / Drug Dosage / Disclaimer Copyright: All rights...

..., instructions or products referred to in the content or advertisements. Blood coagulation Fibrinolysis Liver disease Cancer Thrombosis Haemostasis 2: 209-222 (1973/74) Blood Fibrinolysis in Liver Disease P ieter Bra k m a n, E mile R. M ohler an d T age A stru p The James F. Mitchell Foundation...

...Brandon McMahon; Hau C. Kwaan The fibrinolytic system, more appropriately referred to as the plasminogen activator system, controls not only the intravascular fibrin deposition but also participates in a wide variety of physiologic and pathologic processes. In cancer, the components of this system...

...Chloe Milsom; Janusz Rak Tissue factor (TF), the key regulator of haemostasis and angiogenesis, is also involved in the pathology of several diseases, including cardiovascular, inflammatory and neoplastic conditions. In the latter, TF is upregulated by cancer cells, as well as by certain host cells...

...Netanel Horowitz; Benjamin Brenner Inherited and acquired thrombophilia are well-known risk factors for venous thromboembolism. The incidence of thrombotic events in cancer patients is increased compared to normal population. Data on inherited thrombophilia and cancer is limited. Most studies...

...Chirag Amin; Nigel Mackman; Nigel S. Key Cancer is a prothrombotic state, with an increased prevalence of arterial and venous thromboemboli. Microparticles (MPs) are sub-micron-sized vesicles derived from activated or apoptotic cancer cells and/or host cells that may causally contribute...

...Hugo ten Cate; Anna Falanga Blood coagulation appears to play an important role in the occurrence of cancer and its effects may be twofold. First, in patients with cancer, blood coagulation is activated in the direction of a prothrombotic state. Second, a procoagulant environment may promote cancer...

...Benito Casu; Israel Vlodavsky; Ralph D. Sanderson Low-molecular-weight heparins (LMWH) appear to prolong survival of patients with cancer. Such a beneficial effect is thought to be associated with interruption of molecular mechanisms involving the heparan sulfate (HS) chains of cell surface...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Disintegrin Integrin Metastasis Cancer Melanoma Phosphorylation Wound healing Pathophysiol HaemostThromb 2005;34...

...Hans-Martin M.B. Otten; Martin H. Prins; Susanne M. Smorenburg; Barbara A. Hutten It is well documented that cancer patients undergoing surgery are at a sufficiently high risk of developing venous thromboembolism (VTE) to justify the routine use of prophylactic anticoagulant therapy. However...